Kamada (KMDA) Cut to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Kamada (NASDAQ:KMDA) from a buy rating to a hold rating in a report released on Saturday morning, Zacks.com reports.

According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “

Several other equities research analysts also recently weighed in on the stock. HC Wainwright reaffirmed a buy rating and issued a $11.00 price objective on shares of Kamada in a report on Thursday, February 14th. Chardan Capital reaffirmed a buy rating and issued a $7.00 price objective on shares of Kamada in a report on Friday. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of Buy and an average target price of $8.17.

KMDA stock remained flat at $$5.73 during trading on Friday. 42,218 shares of the company traded hands, compared to its average volume of 58,500. The firm has a market capitalization of $230.71 million, a P/E ratio of 10.42 and a beta of 1.15. Kamada has a 1-year low of $4.63 and a 1-year high of $6.70. The company has a quick ratio of 3.46, a current ratio of 5.29 and a debt-to-equity ratio of 0.04.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.08. The business had revenue of $26.80 million during the quarter, compared to the consensus estimate of $22.87 million. Kamada had a net margin of 20.97% and a return on equity of 24.75%. On average, sell-side analysts expect that Kamada will post 0.48 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in shares of Kamada in the first quarter worth approximately $61,000. Marshall Wace LLP purchased a new stake in shares of Kamada in the first quarter worth approximately $276,000. Renaissance Technologies LLC raised its stake in shares of Kamada by 31.2% in the first quarter. Renaissance Technologies LLC now owns 709,457 shares of the biotechnology company’s stock worth $4,065,000 after purchasing an additional 168,828 shares during the last quarter. Meitav Dash Investments Ltd. raised its stake in shares of Kamada by 3.1% in the first quarter. Meitav Dash Investments Ltd. now owns 909,912 shares of the biotechnology company’s stock worth $5,201,000 after purchasing an additional 27,405 shares during the last quarter. Finally, Acadian Asset Management LLC raised its stake in shares of Kamada by 41.8% in the first quarter. Acadian Asset Management LLC now owns 945,878 shares of the biotechnology company’s stock worth $5,422,000 after purchasing an additional 278,674 shares during the last quarter. 12.60% of the stock is owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.

Featured Article: Options Trading – What is a Straddle?

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.